These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23394910)

  • 1. Increasing use of the vaccine against zoster through recommendation and administration by ophthalmologists at a city hospital.
    Jung JJ; Elkin ZP; Li X; Goldberg JD; Edell AR; Cohen MN; Chen KC; Perskin MH; Park L; Cohen EJ
    Am J Ophthalmol; 2013 May; 155(5):787-95. PubMed ID: 23394910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing herpes zoster through vaccination.
    Gelb LD
    Ophthalmology; 2008 Feb; 115(2 Suppl):S35-8. PubMed ID: 18243932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
    Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
    Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex and herpes zoster eye disease: presentation and management at a city hospital for the underserved in the United States.
    Edell AR; Cohen EJ
    Eye Contact Lens; 2013 Jul; 39(4):311-4. PubMed ID: 23771014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving rates of herpes zoster vaccination with a clinical decision support system in a primary care practice.
    Chaudhry R; Schietel SM; North F; Dejesus R; Kesman RL; Stroebel RJ
    J Eval Clin Pract; 2013 Apr; 19(2):263-6. PubMed ID: 22304668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.
    Lu PJ; Euler GL; Jumaan AO; Harpaz R
    Vaccine; 2009 Feb; 27(6):882-7. PubMed ID: 19071175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to the use of herpes zoster vaccine.
    Hurley LP; Lindley MC; Harpaz R; Stokley S; Daley MF; Crane LA; Dong F; Beaty BL; Tan L; Babbel C; Dickinson LM; Kempe A
    Ann Intern Med; 2010 May; 152(9):555-60. PubMed ID: 20439573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with herpes zoster vaccination status and acceptance of vaccine recommendation in community pharmacies.
    Teeter BS; Garza KB; Stevenson TL; Williamson MA; Zeek ML; Westrick SC
    Vaccine; 2014 Sep; 32(43):5749-54. PubMed ID: 25171848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoster vaccine live.
    Kockler DR; McCarthy MW
    Pharmacotherapy; 2007 Jul; 27(7):1013-9. PubMed ID: 17594207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical and epidemic characteristics of shingles (herpes zoster) and its prevention with vaccines].
    Afonina NM; Mikheeva IV
    Ter Arkh; 2013; 85(11):130-3. PubMed ID: 24432613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Zostavax™--a cohort study in a managed care organization.
    Baxter R; Tran TN; Hansen J; Emery M; Fireman B; Bartlett J; Lewis N; Saddier P
    Vaccine; 2012 Oct; 30(47):6636-41. PubMed ID: 22963800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity.
    Liesegang TJ
    Ophthalmology; 2008 Feb; 115(2 Suppl):S3-12. PubMed ID: 18243930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
    Betts RF
    J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Anterior Segment Complications Associated With the Live Herpes Zoster Vaccine: Evidence From a Health-Claim Database.
    Liu RT; Yeung SN; Carleton B; Etminan M
    Cornea; 2018 Aug; 37(8):952-956. PubMed ID: 29601366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Varicella zoster virus redux.
    Gelb LD
    Herpes; 2009 Jan; 15(3):62-3. PubMed ID: 19306605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine.
    Tseng HF; Smith N; Sy LS; Jacobsen SJ
    Vaccine; 2011 May; 29(20):3628-32. PubMed ID: 21435407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes zoster vaccine awareness among people ≥ 50 years of age and its implications on immunization.
    Javed S; Javed F; Mays RM; Tyring SK
    Dermatol Online J; 2012 Aug; 18(8):2. PubMed ID: 22948052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes Zoster Ophthalmicus.
    Johnson JL; Amzat R; Martin N
    Prim Care; 2015 Sep; 42(3):285-303. PubMed ID: 26319339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.